ABBV AbbVie Inc.

Mentions (100)

• Newszacks.com·15h ago·Neutral

  Why AbbVie (ABBV) Outpaced the Stock Market Today AbbVie (ABBV) closed at $265.85 in the latest trading session, marking a +1.15% move from the prior day.

  View source ↗
• Newsprnewswire.com·19h ago·Negative

  … topline results, Genmab and AbbVie will engage global regulatory authorities NORTH CHICAGO, Ill. and COPENHAGEN, Denmark, Oct. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S  (Nasdaq: GMAB) today announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristi…

  View source ↗
• News (RSS)seekingalpha·2d ago·Neutral

  AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

  View source ↗
• News247wallst.com·2d ago·Neutral

  5 High-Yield Dividend Stocks to Buy for October Income with Cash Flow to Spare From a pharma giant rebuilding after a blockbuster patent loss to a pipeline partnership targeting double-digit distribution raises through 2027, these five stocks span wildly different industries yet share one thing: cash flow that keeps covering the check.

  View source ↗
• News (RSS)fool·3d ago·Negative

  AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think. Another potential blockbuster just joined AbbVie's drug portfolio.

  View source ↗
• Newsfool.com·3d ago·Negative

  AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think. The drug could eventually generate more than $1 billion annually. Once-daily dosing could help the drug gain patient adoption.

  View source ↗
• Newsreuters.com·3d ago·Negative

  AbbVie joins US government pilot to test drug discount rebates US drugmaker AbbVie said on Friday it would participate in a US government ​pilot program aimed at testing a ‌new rebate system for discounted medicines.

  View source ↗
• Newszacks.com·3d ago·Neutral

  Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.

  View source ↗
• News (RSS)fool·4d ago·Positive

  AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.

  View source ↗
• News (Marketaux)gurufocus.com·4d ago·Positive

  AbbVie's Rinvoq Shows Promise in Vitiligo Trials, ABBV Stock Highlights Dividend Concerns On October 01, 2026, AbbVie <em[+208 characters]

  View source ↗
• Newszacks.com·5d ago·Neutral

  AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

  View source ↗
• News247wallst.com·5d ago·Positive

  5 Solid Dividend Stocks to Buy Now An income portfolio built inside one sector carries one set of risks.

  View source ↗
• Newszacks.com·5d ago·Negative

  ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.

  View source ↗
• News247wallst.com·5d ago·Neutral

  5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test) With the 10-year Treasury now paying more than most income stocks, five dividend names face a simple question: does real cash actually back the payout, or just the yield number on the screen?

  View source ↗
• News (RSS)fool·5d ago·Neutral

  AbbVie Stock: Buy, Sell, or Hold in October? The pharmaceutical giant still looks like a stable long-term investment.

  View source ↗
• Newsmarketbeat.com·5d ago·Neutral

  3 Healthcare Dividend Stocks Offering More Than Just Income The flight toward dividend-paying stocks is an example of investors taking what the market is giving. In late September, the yield on the 10-year Treasury note climbed above 5%.

  View source ↗
• News247wallst.com·6d ago·Positive

  BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength Bank of America just raised price targets on two pharma giants facing patent cliffs, but its conviction level differs sharply between them, and the valuation gap may explain which one belongs in a long-term portfolio right now.

  View source ↗
• News (RSS)seekingalpha·6d ago·Neutral

  AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis

  View source ↗
• Newsprnewswire.com·6d ago·Neutral

  AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026 Detailed findings, to be presented in a short oral presentation, demonstrated an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting evaluation of ABBV-295 at dosing intervals beyond weekly administration, including every-other-week and monthly regimens ABBV-295 showed meaningful body weight…

  View source ↗
• Newsprnewswire.com·6d ago·Neutral

  … extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis 1 NORTH CHICAGO, Ill., Sept. 30, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating zumilokibart, in adult patients with moderate to severe atopic dermatitis (AD) will be presented as a late-breaker presentation at the 2026 Annual European Academy of Dermatology and Venereology (EADV) Congress …

  View source ↗
• Newsprnewswire.com·6d ago·Neutral

  …t will also be presented, highlighting AbbVie's ongoing research in additional mechanisms of action NORTH CHICAGO, Ill., Sept. 30, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new research across its diverse dermatology portfolio to be presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, September 30 – October 3 in Vienna, Austria.

  View source ↗
• Newszacks.com·6d ago·Neutral

  AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know AbbVie (ABBV) closed the most recent trading day at $263.29, moving 1.12% from the previous trading session.

  View source ↗
• Newszacks.com·6d ago·Positive

  Defensive Dividends: 3 Companies Investors Can Rely On Several members of the elite Dividend Kings club, including JNJ, KO, and ABBV, are known for dividend reliability, each with a long, consistent history of increasing payouts. The trio boasts a strong defensive nature given consumers' needs for their products no matter the backdrop.

  View source ↗
• Newszacks.com·6d ago·Negative

  AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo ABBV wins FDA approval for Juvmo, expanding its Parkinson's portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.

  View source ↗
• Newsprnewswire.com·7d ago·Negative

  …t journey to advance scientific innovation, strengthen operations and improve outcomes for patients NORTH CHICAGO, Ill., Sept. 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients.

  View source ↗
• Newsbenzinga.com·7d ago·Negative

  AbbVie's New Parkinson's Pill Could Become a Billion-Dollar Drug, Analyst Says On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.'s (NYSE:ABBV) Juvmo (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease.

  View source ↗
• News (RSS)fool·10d ago·Positive

  AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

  View source ↗
• News (RSS)fool·10d ago·Negative

  AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

  View source ↗
• Newsfool.com·10d ago·Neutral

  AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? AbbVie continues to diversify its portfolio into neuroscience and aesthetics to offset the loss of patent exclusivity for older drugs. Johnson & Johnson maintains a massive presence in medical technology alongside its traditional innovative medicine development.

  View source ↗
• Newsreuters.com·10d ago·Negative

  US FDA approves AbbVie's drug for Parkinson's disease The ​US Food ‌and ​Drug ​Administration has ⁠approved ​AbbVie's drug ​for Parkinson's ​disease ​in adults, the ‌health ⁠regulator's website ​showed ​on ⁠Friday.

  View source ↗
• Newsfool.com·10d ago·Negative

  AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? AbbVie is transitioning its revenue base toward newer immunology drugs to offset the decline of its legacy treatments. Pfizer is leaning on heavy investment in oncology and strategic acquisitions to rebuild its growth profile for the future.

  View source ↗
• News247wallst.com·10d ago·Neutral

  ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.

  View source ↗
• News (RSS)fool·11d ago·Negative

  AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

  View source ↗
• Newszacks.com·11d ago·Neutral

  Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio? ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.

  View source ↗
• News (RSS)fool·12d ago·Negative

  Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade It would be hard for investors to replicate the company's return over the past decade.

  View source ↗
• Newsfool.com·12d ago·Neutral

  Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade AbbVie has increased its dividend for 53 consecutive years. It has a strong pipeline and is willing to spend heavily on R&D.

  View source ↗
• Newsseekingalpha.com·12d ago·Negative

  2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie Johnson & Johnson trades at a 30% P/E premium to AbbVie (24.2x vs. 18.8x on FY1 basis). The premium is further amplified on a PEGY basis (4.80x vs. 2.33x) when yield and growth are factored in. However, JNJ's premium is well justified by its conservative balance sheet and superior capital allocation flexibility.

  View source ↗
• Newszacks.com·13d ago·Positive

  AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis ABBV's Rinvoq secures EU approval for pJIA in children, expanding ABBV's reach as clinical data show sustained improvements in disease activity.

  View source ↗
• Newsfool.com·14d ago·Positive

  AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? Dividend payments offer you security in difficult markets -- and extra growth in better times. These pharma companies offer dividend yields that beat the dividend yield of the S&P 500.

  View source ↗
• News247wallst.com·14d ago·Neutral

  3 Dividend Stocks to Buy Before September Ends and Hold Forever With the third quarter closing out, income investors have a narrow window to lock in three cash-generative blue chips before Q3 earnings reset expectations. The shared hook: recession-resilient franchises, multi-decade dividend histories, and reaffirmed or raised 2026 guidance.

  View source ↗
• Newsprnewswire.com·14d ago·Negative

  …ed in the European Union for 11 indications across various immune-mediated, inflammatory diseases 1 NORTH CHICAGO, Ill., Sept. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), in patients two years of…

  View source ↗
• News (RSS)investing·14d ago·Negative

  Pete Sessions from Texas’s 17th Congressional District Sells Shares in AbbVie and Alphabet

  View source ↗
• News (RSS)investing·14d ago·Negative

  AbbVie partners with Iambic on AI drug discovery collaboration

  View source ↗
• Newsprnewswire.com·15d ago·Negative

  AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology Companies to pursue programs with both first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertise NORTH CHICAGO, Ill. and SAN DIEGO, Sept.

  View source ↗
• News (Marketaux)finance.yahoo.com·16d ago·Positive

  AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now? AbbVie (NYSE: ABBV[+306 characters]

  View source ↗
• Newsfool.com·16d ago·Neutral

  AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now? AbbVie's Qulipta could be racing toward another label expansion, given a recent clinical trial win. This new indication could make a meaningful impact on Qulipta's sales.

  View source ↗
• News (RSS)fool·17d ago·Positive

  AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.

  View source ↗
• Newsfool.com·18d ago·Positive

  AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? AbbVie continues to diversify its revenue streams with successful expansions in immunology and aesthetics. Bristol-Myers Squibb maintains high net margins while offering a significantly lower valuation than many industry peers.

  View source ↗
• Newsprnewswire.com·18d ago·Positive

  …ls can also be achieved in routine practice, where patients often have more complex treatment needs NORTH CHICAGO, Ill., Sept. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today presented new VRAYLAR® (cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major depressive disorder (MDD) and bipolar I disorder (BP-I).

  View source ↗
• News247wallst.com·18d ago·Neutral

  5 Stocks, 5 Different Industries, 1 Thing in Common: Reliable Income A biopharma giant, a chip maker, a delivery network, a trash hauler, and an oncology powerhouse walk into the same portfolio for one reason, and it has nothing to do with chasing the highest yield.

  View source ↗
• News (RSS)investing·18d ago·Neutral

  AbbVie to present phase 3 etentamig data at myeloma meeting

  View source ↗
• Newszacks.com·19d ago·Positive

  How AbbVie's Neuroscience Portfolio Has Transformed Over the Years ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.

  View source ↗
• Newszacks.com·20d ago·Neutral

  Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

  View source ↗
• Newsseekingalpha.com·20d ago·Positive

  AbbVie Inc. (ABBV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript AbbVie Inc. (ABBV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  View source ↗
• Newsmarketbeat.com·20d ago·Negative

  AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline AbbVie NYSE: ABBV executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company's established SKYRIZI and RINVOQ franchises.

  View source ↗
• Newsfool.com·21d ago·Neutral

  Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside Citadel, Ken Griffin's hedge fund, materially increased its stake in AbbVie; here's why you may want to follow that lead.

  View source ↗
• Newszacks.com·21d ago·Neutral

  AbbVie (ABBV) Advances While Market Declines: Some Information for Investors The latest trading day saw AbbVie (ABBV) settling at $261.7, representing a +1.78% change from its previous close.

  View source ↗
• News (RSS)fool·24d ago·Neutral

  Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock? AbbVie's dividend is a very appealing factor.

  View source ↗
• Newsfool.com·24d ago·Neutral

  Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock? AbbVie is a diversified pharmaceutical company. Its dividend yields 2.7% -- and that payout has been growing.

  View source ↗
• Newszacks.com·24d ago·Neutral

  AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study ABBV's atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.

  View source ↗
• News (Marketaux)gurufocus.com·24d ago·Positive

  ABBV Looks 15.8% Overvalued on GF Value™ as Dividend Sustainability Remains Key On September 11, 2026, Ipsen announced p[+211 characters]

  View source ↗
• News247wallst.com·25d ago·Positive

  How Much Dividend Income Can You Buy With $250,000? A $250,000 rollover sounds like a clean starting point until you realize yield alone is not the whole story, and only one name on this roster actually clears the current Treasury rate.

  View source ↗
• News (RSS)investing·25d ago·Neutral

  AbbVie declares quarterly dividend of $1.73 per share

  View source ↗
• News (RSS)fool·25d ago·Positive

  AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

  View source ↗
• Newsprnewswire.com·25d ago·Negative

  AbbVie Declares Quarterly Dividend NORTH CHICAGO, Ill., Sept. 10, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.

  View source ↗
• Newsfool.com·25d ago·Negative

  AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? AbbVie is successfully transitioning its revenue base toward newer immunology drugs to offset the loss of patent protection for Humira. Novo Nordisk maintains a dominant position in the rapidly expanding global markets for diabetes and obesity treatments.

  View source ↗
• Newszacks.com·25d ago·Neutral

  AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.

  View source ↗
• Newsseekingalpha.com·26d ago·Neutral

  ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie ADARx Pharmaceuticals is pursuing an IPO to fund its ambitious RNA-targeted therapy pipeline, targeting serious hepatic and non-hepatic diseases. ADRX's lead candidate, Onvuzosiran for hereditary angioedema, is in Phase 3 with topline data expected by end of 2027 and potential NDA in 2028. A substantial collaboration with AbbVie provided $335 million in upfront cash, $385 million in option payments, and up to $7.45 billion …

  View source ↗
• Newsseekingalpha.com·26d ago·Positive

  AbbVie Inc. (ABBV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript AbbVie Inc. (ABBV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

  View source ↗
• Newsmarketbeat.com·26d ago·Positive

  AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference AbbVie NYSE: ABBV executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit its long-term strategy.

  View source ↗
• News (Marketaux)finance.yahoo.com·26d ago·Neutral

  Billionaire Israel Englander Is Doubling Down on These 2 Outstanding Dividend Stocks. Should You? During the second quarter, Izzy Englande[+311 characters]

  View source ↗
• Newszacks.com·27d ago·Neutral

  AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note In the most recent trading session, AbbVie (ABBV) closed at $248.78, indicating a -2.99% shift from the previous trading day.

  View source ↗
• News (RSS)seekingalpha·30d ago·Neutral

  Key deals this week: Flex, Nvidia, AbbVie and more

  View source ↗
• Newsfool.com·31d ago·Positive

  3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King) Owning these dividend stocks could be a simple way to make money over the long term.

  View source ↗
• News (RSS)fool·31d ago·Positive

  AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

  View source ↗
• Newsfool.com·31d ago·Negative

  AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie has successfully pivoted to new immunology leaders to offset the loss of exclusivity for its top-selling drug. Pfizer is utilizing its robust cash position to acquire oncology assets and replenish its product pipeline.

  View source ↗
• Newszacks.com·31d ago·Neutral

  ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.

  View source ↗
• News247wallst.com·32d ago·Negative

  AbbVie's Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing? AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.

  View source ↗
• News (RSS)seekingalpha·32d ago·Neutral

  AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis)

  View source ↗
• Newsseekingalpha.com·32d ago·Positive

  … a 'Buy', supported by robust fundamentals, a strong immunology portfolio, and attractive valuation metrics. The recent $11B Apogee Therapeutics acquisition enhances ABBV's pipeline in immunology, oncology, neuroscience, and aesthetics, with only modest near-term EPS dilution. Q2 results beat expectations, driven by Skyrizi and Rinvoq, while technicals and momentum favor continued upside toward a $292 price target.

  View source ↗
• News (Marketaux)gurufocus.com·32d ago·Positive

  ABBV Looks 18.1% Overvalued on GF Value™ Amid Dividend Strength On September 03, 2026, AbbVie <[+345 characters]

  View source ↗
• News (Marketaux)gurufocus.com·32d ago·Positive

  ABBV Looks 18.6% Overvalued on GF Value™ as Dividend Sustainability Remains Key On September 03, 2026, AbbVie <[+279 characters]

  View source ↗
• Newszacks.com·32d ago·Negative

  ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell? AbbVie's Skyrizi, Rinvoq and neuroscience drugs drive growth, but Humira erosion, oncology and Aesthetics remain key headwinds.

  View source ↗
• Newsreuters.com·33d ago·Negative

  AbbVie's blood cancer drug meets late-stage trial goals AbbVie ​said on ‌Thursday ​its ​drug for ⁠a ​type ​of blood cancer ​has ​met the ‌main ⁠goals of ​a ​late-stage ⁠trial.

  View source ↗
• Newsprnewswire.com·33d ago·Neutral

  …gager, to enable treatment across a range of settings, including outpatient and community-based care NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 CERVINO study1 evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed (proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody) relapsed/refractory mu…

  View source ↗
• Newsprnewswire.com·33d ago·Positive

  …4.07; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88 NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE).

  View source ↗
• Newsprnewswire.com·33d ago·Neutral

  AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026.

  View source ↗
• Newszacks.com·35d ago·Neutral

  Aging Population Drives Healthcare Growth: Stocks to Watch AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.

  View source ↗
• Newsprnewswire.com·36d ago·Neutral

  AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference NORTH CHICAGO, Ill., Aug. 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.

  View source ↗
• Newsdefenseworld.net·37d ago·Negative

  Great Lakes Advisors LLC Makes New Investment in AbbVie Inc. $ABBV Great Lakes Advisors LLC bought a new stake in AbbVie Inc. (NYSE: ABBV) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 536,227 shares of the company's stock, valued at approximately $134,936,000. AbbVie comprises about 1.0%

  View source ↗
• Newsdefenseworld.net·37d ago·Negative

  Danske Bank A S Purchases New Position in AbbVie Inc. $ABBV Danske Bank A S acquired a new position in AbbVie Inc. (NYSE: ABBV) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,316,850 shares of the company's stock, valued at approximately $331,372,000. AbbVie accounts for about 0.7% of Danske Bank A S's holdings,

  View source ↗
• Newsdefenseworld.net·37d ago·Neutral

  Compass Wealth Management LLC Acquires New Position in AbbVie Inc. $ABBV Compass Wealth Management LLC purchased a new stake in shares of AbbVie Inc. (NYSE: ABBV) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 25,828 shares of the company's stock, valued at approximately $6,499,000. AbbVie makes up 1.2% of Compass Wealth

  View source ↗
• Newsdefenseworld.net·37d ago·Negative

  Danica Pension Livsforsikringsaktieselskab Purchases Shares of 93,612 AbbVie Inc. $ABBV Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of AbbVie Inc. (NYSE: ABBV) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 93,612 shares of the company's stock, valued at approximately $23,557,000. Other hedge funds and other institutional investors also

  View source ↗
• Newsdefenseworld.net·37d ago·Negative

  Gables Capital Management Inc. Makes New $849,000 Investment in AbbVie Inc. $ABBV Gables Capital Management Inc. acquired a new stake in AbbVie Inc. (NYSE: ABBV) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,374 shares of the company's stock, valued at approximately $849,000. Several other large investors also recently modified their

  View source ↗
• Newsdefenseworld.net·37d ago·Negative

  Burke & Herbert Bank & Trust Co. Sells 2,747 Shares of AbbVie Inc. $ABBV Burke and Herbert Bank and Trust Co. reduced its position in AbbVie Inc. (NYSE: ABBV) by 12.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,061 shares of the company's stock after selling 2,747 shares during the period. AbbVie

  View source ↗
• Newsdefenseworld.net·37d ago·Negative

  Empirical Asset Management LLC Takes Position in AbbVie Inc. $ABBV Empirical Asset Management LLC acquired a new position in AbbVie Inc. (NYSE: ABBV) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,575 shares of the company's stock, valued at approximately $1,403,000. Several other large investors have also modified their holdings

  View source ↗
• News (RSS)yahoo·37d ago·Positive

  AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

  View source ↗
• News (RSS)fool·37d ago·Positive

  AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

  View source ↗
• News (RSS)yahoo·37d ago·Positive

  AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

  View source ↗
• News (RSS)fool·37d ago·Positive

  AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

  View source ↗